The NSCLC Content Hub Channel

Dr. Goldman on the Use of Immunotherapy in Oncogene-Driven NSCLC

In this video interview, Jonathan W. Goldman, MD, a health sciences clinical instructor in the Department of Medicine at the Jonsson Comprehensive Cancer Center Signal Transduction and Therapeutics Program at UCLA, discusses data regarding the use of immunotherapy for oncogene-driven non-small cell lung cancer (NSCLC), specifically cases with EGFR mutations or ALK fusions.

Learn more by clicking here.

More in NSCLC Content Hub

► 1:15

Dr. Socinski on Recommendations for Molecular Testing in Lung Cancer

NSCLC Content Hub

Mark A. Socinski, MD, executive medical director at AdventHealth Cancer Institute, recommends immediate comprehensive molecular testing at the time of lung cancer diagnosis. Stating that oncogenic driver mutation identification is...

► 1:20

Dr. Bertino on Frontline Dacomitinib in Metastatic EGFR+ NSCLC

NSCLC Content Hub

Erin M. Bertino, MD, medical oncologist at Ohio State University Comprehensive Cancer Center - James, provides a comparison of newly approved drug dacomitinib versus the other available FDA-approved EGFR tyrosine...

► 3:51

Importance of Biomarker Testing for RET in Non Small Cell Lung Cancer

NSCLC Content Hub

Jessica Bauman, MD, assistant professor of hematology/oncology at Fox Chase Cancer Center, discusses recent advancements in non-small cell lung cancer (NSCLC) treatment using targeted RET-fusion mutation therapies. RET-fusion driver mutations...

► 1:01

Dr. Rotow on the Implications of Next-Generation ALK Inhibitors in NSCLC

NSCLC Content Hub

Julia Rotow, MD, medical oncologist at Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute, reviews new treatment options for non-small cell lung cancer (NSCLC) patients. Dr. Rotow recommends next-generation...